Matinas BioPharma Holdings, Inc. (MTNB)
2.64
+0.22
(+9.09%)
USD |
NYAM |
Oct 02, 16:00
2.83
+0.19
(+7.20%)
After-Hours: 20:00
Matinas BioPharma Holdings Enterprise Value : 0.3225M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 0.3225M |
| October 01, 2026 | 0.2286M |
| September 30, 2026 | 0.2841M |
| September 29, 2026 | 0.425M |
| September 28, 2026 | 0.2756M |
| September 25, 2026 | 0.22M |
| September 24, 2026 | 0.3354M |
| September 23, 2026 | 0.3161M |
| September 22, 2026 | 0.3289M |
| September 21, 2026 | 0.3091M |
| September 18, 2026 | 0.2226M |
| September 17, 2026 | 0.2393M |
| September 16, 2026 | 0.2527M |
| September 15, 2026 | 0.22M |
| September 14, 2026 | 0.425M |
| September 11, 2026 | 0.3802M |
| September 10, 2026 | 0.5083M |
| September 09, 2026 | 0.3719M |
| September 08, 2026 | 0.361M |
| September 04, 2026 | 0.361M |
| September 03, 2026 | 0.3546M |
| September 02, 2026 | 0.3866M |
| September 01, 2026 | 0.4616M |
| August 31, 2026 | 0.4616M |
| August 28, 2026 | 0.4763M |
| Date | Value |
|---|---|
| August 27, 2026 | 0.4763M |
| August 26, 2026 | 0.4532M |
| August 25, 2026 | 0.459M |
| August 24, 2026 | 0.4539M |
| August 21, 2026 | 0.4686M |
| August 20, 2026 | 0.3642M |
| August 19, 2026 | 0.739M |
| August 18, 2026 | 0.50M |
| August 17, 2026 | 0.6185M |
| August 14, 2026 | 0.6941M |
| August 13, 2026 | 0.6877M |
| August 12, 2026 | 0.7326M |
| August 11, 2026 | 0.8735M |
| August 10, 2026 | 0.9183M |
| August 07, 2026 | 1.008M |
| August 06, 2026 | 0.9145M |
| August 05, 2026 | 0.9568M |
| August 04, 2026 | 1.056M |
| August 03, 2026 | 1.127M |
| July 31, 2026 | 1.077M |
| July 30, 2026 | 1.228M |
| July 29, 2026 | 1.104M |
| July 28, 2026 | 1.072M |
| July 27, 2026 | 1.322M |
| July 24, 2026 | 0.7415M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
| Vericel Corp. | 1.987B |
| Biogen, Inc. | 39.55B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.326M |
| Total Expenses (Quarterly) | 1.326M |
| EPS Diluted (Quarterly) | -3.105 |
| Earnings Yield | -682.3% |
| Normalized Earnings Yield | -705.14 |